AAM
IBB icon

Aberdeen Asset Management’s iShares Biotechnology ETF IBB Stock Holding History

Aberdeen Asset Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$634K Sell
6,135
-537
-8% -$52.9K ﹤0.01% 703
2017
Q1 		$652K Sell
6,672
-1,332
-17% -$128K ﹤0.01% 692
2016
Q4 		$708K Buy
+8,004
New +$728K ﹤0.01% 674

Other funds holding IBB

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
CM
Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Aberdeen Asset Management's IBB Position: Q2 2017 in Review

Aberdeen Asset Management reduced its iShares Biotechnology ETF (IBB) stake by 8% in Q2 2017, selling an estimated $52.9K and leaving 6,135 shares worth $634K. The position accounts for ﹤0.01% of the portfolio, ranked #703.

Aberdeen Asset Management first reported a position in IBB in Q4 2016 and has held it in 3 quarters since. The position peaked at $708K in Q4 2016. 562 funds tracked by Wall St. Rank hold IBB as of Q2 2017.

  • Aberdeen Asset Management held 6,135 shares of iShares Biotechnology ETF worth $634K as of Q2 2017.
  • Aberdeen Asset Management sold 537 iShares Biotechnology ETF shares in Q2 2017, an estimated $52.9K.
  • iShares Biotechnology ETF made up ﹤0.01% of Aberdeen Asset Management's portfolio in Q2 2017, its #703 holding.
  • Aberdeen Asset Management first reported a position in iShares Biotechnology ETF in Q4 2016 and has held it in 3 quarters since.
  • Aberdeen Asset Management's iShares Biotechnology ETF position peaked at $708K in Q4 2016.
  • 562 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2017.

Based on Aberdeen Asset Management's 13F filing for Q2 2017, filed 10 Aug 2017.